15. Gillette, J.R. (1979). Drug Metab. Revs.10, 59–87.
16.
16. Walker, C.H. (1978). Drug Metab. Revs.7, 295–323.
17.
17. Hodgson, E. (1979). Drug Metab. Revs.10, 15–33.
18.
18. Ahmad, S. (1979). Drug Metab. Revs.10, 1–14.
19.
19. Vesell, E.S. (1980). In: Molecular and Cellular Aspects of Cracinogen Screening. R. Montesano, H. Bartsch, and L. Tomatis (eds.). IARC Scientific Publication No. 27, International Agency for Research on Cancer: Lyon. pp. 23–40.
21. Caldwell, J., Williams, R.T., Bassir, O., and French, M.R. (1977). Eur. J. Drug Metab. Pharmacokin.3, 61
22.
22. Caldwell, J. (1974). In: Enzymatic Basis of Detoxification. W. Jakoby (ed.). Academic Press: New York. p. 927.
23.
23. Dring, L.G. (1976). In: Drug Metabolism from Microbe to Man. D. V. Parke and R. L. Smith (eds.). Taylor and Francis: London, p. 281.
24.
24. Dicarlo, F.J. (1982). Drug Metab. Revs.13, 1–4.
25.
25. National Academy of Sciences (1980). Principles of Toxicological Interactions Associated with Multiple Chemical Exposure. National Academy of Sciences: Washington, DC.
26.
26. Vesell, E.S. (1982). Clin. Pharmacol.31, 1–7.
27.
27. Alvares, A.P., Pantuck, E.J., Anderson, K.E., Kappas, A., and Conney, A.H. (1979). Drug Metab. Revs.9, 185–205.
28.
28. Dollery, C.T., Fraser, H.S., Mucklow, J.C., and Bulpitt, C.J. (1979). Drug Metab. Revs.9, 207–220.
30. Dagani, R. (1981). Chem. Eng. News, Nov.2318–19.
31.
31. Jusko, W.J. (1979). Drug Metab. Revs.9, 221–236.
32.
32. Campbell, T.C., Hayes, J.R., Merrill, Jr., A.H., Maso, M., and Goetchius, M. (1979). Drug Metab. Revs.9, 173–184.
33.
33. Vesell, E.S. (1980). In: Clinical Pharmacology and Therapeutics. P. Turner (ed.). Proceedings of the First World Conference. Macmillan: London, pp. 63–79.
34.
34. Ritchie, J.C., Sloan, T.P., Idle, J.R., and Smith, R.L. (1980). In: Environmental Chemicals, Enzyme Function and Human Disease. Ciba Foundation Symposium No. 76. pp. 219–244.
35.
35. Eichelbaum, M. (1982). Clin. Pharmacokinetics7, 1–22.
36.
36. Harris, H. (1970). In: Frontiers of Biology: The Principles of Human Biochemical Genetics, Vol. 19. A. Neuberger and E. L. Tatum (eds.). Elsevier: New York. pp. 107–140.
37.
37. Atlas, S.A. and Nebert, D.W. (1977). In: Drug Metabolism from Microbe to Man. D. V. Parke and R. L. Smith (eds.). Taylor and Francis: London. pp. 393–430.
38.
38. Boobis, A.R. (1979). In: Drug Toxicity. J. W. Gorrod (ed.). Taylor and Francis: London. pp. 51–89.
39.
39. Price-Evans, D.A. (1977). In: Drug Metabolism from Microbe to Man. D. V. Parke and R. L. Smith (eds.). Taylor and Francis: London. pp. 369–391.
42. Mitchell, J.R., Thorgeirsson, W.D., Black, M.J., Timbrell, J.A. et al. (1975). Clin. Pharmacol. Ther.18, 70–79.
43.
43. Eichelbaum, M., Spannbrucker, N., and Dengler, H.J. (1978). In: Biological Oxidation of Nitrogen. J. Gorrod (ed.). Elsevier/North Holland Biomedical Press: Amsterdam. pp. 113–118.
44.
44. Eichelbaum, M., Spannbruches, N., Steincke, B., and Dengler, H.J. (1979). Eur. J. Clin. Pharm.16, 183–187.
45.
45. Mahgoub, A., Idle, J.R., Dring, L.G. et al. (1977). Lancet2, 584–586.
47. Higginson, J. (1980). J. Toxicol. Env. Hlth.6(5-6). 941–951.
48.
48. Higginson, J. (1981). Food Cosmet. Toxicol.19, 539–548.
49.
49. Higginson, J. (1979). In: Carcinogens: Identification and Mechanisms of Action. A. C. Griffin and C. R. Shaw (eds.). Raven Press: New York, p. 187.
50.
50. Weisburger, J.H., Cohen, L.A., and Wynder (1977). In: Origins of Human Cancer. Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. pp. 567–602.
51.
51. Clayson, D.B. (1975). Cancer Res.35, 3292–3300.
52.
52. Hietanen, E. (1980). J. Toxicol. Env. Hlth.6(5-6), 963–969.
53.
53. Adelstein, A.M. (1980). J. Toxicol. Env. Hlth.6(5-6), 953–962.
54.
54. Mulvihill, J.J. (1982). J. Natl. Cancer Inst.68, 173–174.
55.
55. Falk, H.L. (1976). Oncology33, 77–85.
56.
56. Miller, J.A. and Miller, E.C. (1977). In: Origins of Human Cancer, Vol. B. H. H. Hiatt, J. D. Watson, and J. A. Winsten (eds.). Cold Spring Harbor Laboratories: Cold Spring Harbor, NY. pp. 605–627.
57.
57. Heidelberger, C. (1975). Ann. Rev. Biochem.44, 79–121.
58.
58. Bresnick, E. (1978). Adv. Enz. Reg.16, 347–361.
59.
59. Bresnick, E. and Eastman, A. (1982). Drug. Metab. Revs.13, 189–205.
60.
60. Nebert, D.W. and Atlas, J.A. (1978). Human Genet.1, 149–160.
61.
61. Roe, F.J.C. and Clack, J. (1964). Brit. J. Cancer17, 596–604.
62.
62. Van Duuren, B.L. (1981). J. Environ. Pathol. Toxicol.5(1), 959–969.
63.
63. Doll, R. and Hill, A.B. (1964). Brit. Med. J.i, 1399–1410, 1460-1467.
64.
64. Wynder, E.L. (1970). J. Am. Med. Assoc.213, 2221–2228.
65.
65. Selikoff, I.J. (1968). J. Am. Med. Assoc.204, 106–122.
66.
66. Wynder, E.L. (1977). J. Am. Dietetic Assoc.71, 385–391.
67.
67. Oiso, T. (1975). Cancer Res.35, 3254
68.
68. Hirayama, T. (1975). Excerpta Med.3, 26
69.
69. MacMAHON, B., Cole, P., and Brown, J.J. (1973). Natl. Cancer Inst.50, 21
70.
70. Wynder, E.L., Bross, I.J., and Hirayama, T. (1960). Cancer13, 559
71.
71. Chan, P.C. and Cohen, L.A. (1974). J. Natl. Cancer Inst.52, 25
72.
72. Modan, B. (1977). Cancer40, 1887–1891.
73.
73. Fouts, J.R. (1963). Ann. NY Acad. Sci.104, 875
90. Bollag, W. (1971). Cancer Chemother. Rep.55, 53–55.
91.
91. Newberne, P.M. and Suphakarn, V. (1977). Cancer40, 2553–2556.
92.
92. Newberne, P.M. and Rogers, A.E. (1976). In: Fundamentals in Cancer Prevention. P. N. Magee, S. Takayama, T. Sugamura, and T. Matsushima (eds.). University of Tokyo Press: Tokyo. pp. 15–40.
93.
93. Wattenberg, L.W. (1978). J. Natl. Cancer Inst.60, 11–17.
94.
94. Wattenberg, L.W. (1972). J. Natl. Cancer Inst.48, 1425–1430.